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Summary.-In a case-control study, we investigated 169 women aged 15-49 years
with malignant melanoma notified to the Oxford and South Western cancer registries
during the years 1971-76, together with 507 matched controls. Data about medical,
reproductive, drug and smoking histories were obtained both by reviewing general
practitioner (GP) records and from the women themselves by postal questionnaires.
There was no significant evidence of any overall increase in the risk of melanoma in
oral contraceptive (OC) users (data from GP records-ever use vs never use, relative
risk (RR) 1.34, 9500 confidence limits 0.92-1 96; corresponding data from postal
questionnaires-RR 1-13, limits 0.73-1-75). However, although not significant, the
risk estimated from data in the postal questionnaires was higher in women who had
used OCs for 5 years or more (use ;5 yrs vs never use, RR 1.57, limits 0-83-3.03).
Previously demonstrated risk factors for melanoma, such as fair skin, blonde or red
hair and Celtic origin were found to be commoner in the cases than in the controls.
Data from the Oxford/Family Planning Association contraceptive study were also
examined. Unexpectedly there was a strong suggestion of a negative association
between OC use and melanoma risk, but the analysis was based on only 12 women
with the disease.
ALTHOUGH MALIGNANT MELANOMA re-
mains a relatively rare tuimour, the inci-
dence of and mortality from the disease
have increased more in recent years than
those of most other cancers. These in-
creases have been noted in both sexes
and across all age groups, though they
appear most pronounced in the middle-
aged (Elwood & Lee, 1975; Lee, 1976;
Magnus, 1977; Teppo et al., 1978; Malec &
Eklung, 1978; Lee & Strickland, 1980).
In 1977, Beral et al. reported an association
between oral contraceptive (OC) use and
malignant melanoma in 3 separate sets of
data collected in California. However,
the association reached statistical sig-
nificance in only one set; amongst almost
18,000 women aged 17-59 years registered
with a health-maintenance organization,
a history ofskin cancer was more common
in those who had used OCs, particularly
those with a duration of use of 4 years or
more. Unfortunately, the analyses were
based on small numbers of women with
malignant melanoma, and no data were
available on possible confounding vari-
ables, such as exposure to sunlight.
An association between OCs and malig-
nant melanoma would be biologically
plausible. First, large doses ofoestrogen, or
smaller doses given with simultaneous
progestogen, have been shown to increase
both the melanocyte count and the intra-
cellular and extracellular melanin content
in guinea pigs (Sneu & Bischitz, 1960).
Secondly, oestrogen receptors have been
found in human malignant melanoma cells
(Fisher et al., 1976). Finally, one of the
more commonly reported side effects of
OC use is hyperpgimentation, especially ofS. A. ADAM ET AL.
the face, which increases in incidence
with duration of OC use (Jelinek, 1970;
Carruthers, 1966).
California is a high-risk area for mela-
noma, whereas the incidence rates in the
United Kingdom are consistently low
(Waterhouse et al., 1976). Accordingly,
we decided to investigate the relationship
between OCs and malignant melanoma, to
see whether the findings for California
were replicated in a population of women
living in southern England.
METHOD
We identified all newly diagnosed cases of
malignant melanoma of the skin in white,
British women aged 15-49 years notified to
the cancer registries in the Oxford Region
(during 1971-6) and the South Western
Region, excluding women resident in Devon
and Cornwall (during 1971-3). With the per-
mission of the appropriate consultant, the
hospital notes relating to each case were
reviewed to verify the histological diagnosis
and to obtain the name of each patient's
general practitioner (GP). The GP was then
contacted and arrangements made for a
research wAorker to visit the practice. During
the visit, the GP records (obtained from the
Family Practitioner Committee if the patient
had died) wvere reviewed to obtain data on
the activity of the disease, past medical
history, reproductive history, use of drugs,
smoking history and occupation. At the same
time, 3 female controls matched by age group
(15-19, 20-24, 25-29, 30-34, 35-39, 40-44,
45-49 years) and marital status (ever married,
never married) were randomly selected for
each case from the GP's practice list and
similar information was extracted from their
GP records. For both cases and controls the
recording of information was limited to the
period preceding the date of diagnosis of the
melanoma. In addition, each GP was inter-
viewed to supplement and verify the data
extracted from the practice records. In the
few instances where the woman with mela-
noma had subsequently moved away from
the Oxford or South Western Health Regions,
the controls were selected from the practice
ofthe GP with whom she had been registered
at the time of diagnosis of the disease. We
also contacted the new GP, by post or tele-
phone, in order to obtain the patient's present
address, and to find out whether or not the
disease was currently active.
With the permission of the GP, a postal
questionnaire wras sent to each living case
(excluding one woman with active melanoma)
and to each control. We asked for information
about medical, reproductive, drug and smok-
ing histories, and also about possible con-
founding variables such as colouring (hair,
eyes and skin) and exposure to sunlight (type
of occupation, outdoor leisure activities, and
holidays and residence abroad). Up to 3 postal
questionnaires were sent to each woman. No
further attempt was made to contact those
women who did not return the questionnaire,
as some consultants and GPs had expressed
reservations about our approaching their
patients directly.
In addition to the case-control study, we
also extracted data on the incidence of
melanoma up to the end of 1980 among the
17,032 women using different methods of
birth control recruited to the Oxford/Family
Planning Association contraceptive study
during the period 1969-74 (Vessey et al.,
1976).
RESULTS
A total of 169 women with malignant
melanoma were identified in the case-
control study; 121 in the Oxford Region
and 48 in the South Western Region. All
the hospital records were found and
reviewed. The sites ofthe primary tumours
were: 88 (52%) on the lower leg, 19 (11%)
on the thigh, 26 (15%) on the upper limb,
23 (14%) on the trunk and 10 (6%) on
the head or neck. In 3 cases (2%) no
primary site was identified. We were able
to review the GP records for 158 (93%0)
ofthe cases and 503 (99%o) ofthe controls.
TABLE L.-lumbers (°O) of women com-
pleting thepostal questionnaire
Questionnaire completed
1st mailing
2nd mailing
3rd mailing
Questionnaire not
completed
Questionnaire not sent*
Total
Cases
111 (66)
90 (53)
19 (11)
2 (1)
24 (14)
34 (20)
Controls
342 (68)
263 (53)
61 (12)
18 (4)
158 (31)
7 (1)
169 507
* 33 cases were dead and I case had active disease.
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The response rates to the postal question-
naire are shown in Table I. By the time of
the study, 33 cases (20%) were dead and
another one had active disease; in addi-
tion, 7 controls were not sent the question-
naire at the request of their GP. Eighty-
two per cent of cases and 68O% of controls
who were sent a questionnaire completed
and returned it, resulting (fortuitously) in
similar overall percentages of women
providing information in both groups.
The data suggest, however, that women
who have had melanoma are more moti-
vated to help with research into "skin
conditions" (the wording used in our
covering letter) than women free from the
disease which should be borne in mind
when interpreting the results.
At the outset, we decided to analyse
the data on an uinmatched basis rather
than a matched one. Althoughinformation
from the GP records was available on
almost, all cases and controls, these records
included few data about possible con-
founding variables. In addition, there was
incompleteness in the ascertainment of
questionnaire data (some cases having
fewer than 3 completed controls, some
controls have no corresponding completed
case). Accordingly, matched analyses could
have been carried out only to a limited
extent.
The distribution of all 169 cases bv age
group is shown in Table II. The data
illustrate the increase in the incidence of
melanoma with age. When comparisons
were made between the 158 cases and 503
controls for whom the GP records were
available, the age and marital-status
distributions were found to be closely
TABLE II.-Distribution (Oo)
ofcases
Age-group
15-19
20-24
95-29
30-34
35-39
40-44
45-49
Total
by age-yroup
Cases
6 (4)
7 (4)
21 (12)
27 (16)
26 (15)
34 (20)
48 (28)
169
similar. The same was true when the
analysis was restricted to the III cases
and 342 controls who returned a postal
questionnaire. In addition, there were no
important, differences between these cases
and controls with respect to social class,
number of children, past medical history
(including a history of difficulty in con-
ceiving) or smoking history.
Our main puirpose in carrying out this
study was to re-examine the relationship
between OCs and malignant melanoma.
Table III (based on postal questionnaire
TABLE III. Numibers of wronmen using oral
contraceptives according to postal ques-
tionnaire (percentages of those wvith ade-
quate information)
D)uration of tuse
of OCs Cases Controls
Never
1-5 monthis
6-11 mointhls
12-23 mont,hs
24-59 montlhs
5 years or more
Usedl OCs, dutirati(on
not kniown
Ina(lequate
iinformatioI
Total
66 (60)
3 (3)
5 (5)
2 (2)
12 (11)
17 (15)
5 (5)
214 (63)
10 (3)
12 (4)
13 (4)
37 (I1)
35 (10)
1'9 (6)
59 167
169 507
data provided by the women themselves)
shows that almost two-thirds of both
cases and controls for whom information
was available had never used OCs (ever
use vs never use, RR= 1 l3, 950O con-
fidence limits 0-73-1-75) and that the dura-
tion of use for those who had taken OCs
was broadly similar for the two groups.
However, it should be noted that in the
small group of women who had used OCs
for 5 years or more there was an RR of
1-59 (limits 0 83-3.03). Although this is
not statistically significant, it is in this
group of women that an effect of OC use
might be most likely, and thus the appa-
rent similarity of OC use between cases
and controls should be interpreted
cautiously. Amongst the women who had
used OCs, similar proportions of cases and
controls (18%) were current users at the
time the case was diagnosed as having
melanoma.
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TABLE IV. Numbers of women using OCs
according to GP records (percentages of
those with adequate informiation)
Duration of use
of OCs
Never
1-5 months
6-11 montlhs
12-23 months
24-59 months
5 years or more
Used OCs, dluration
not known
Inadequate
information
Total
Cases
94 (62)
5 (3)
5 (3)
5 (3)
14 (9)
6 (4)
23 (15)
17
169
Controls
344 (69)
26 (5)
10 (2)
20 (4)
36 (7)
15 (3)
51 (10)
5
507
A separate analysis of the data on OC
use obtained from the GP records, which,
unlike the questionnaire data, included the
women who subsequently died, also failed
to reveal any significant differences (Table
IV). The overall RR was, however, slightly
raised (ever use vs never use, RR= 1P34,
limits 0-92-1.96). The percentages of
ever users and, in particular, long-term
users were lower than in the questionnaire
data for both cases and controls; this
probably reflects incomplete GP records
because some women obtained OCs from
family-planning clinics. Data from the
GP records did not reveal any differences
in OC use between those who survived
and those who died of their melanoma.
Data were also collected on the use of
other hormone preparations. According to
the GP's records, 40%o of cases and 4500
ofcontrols had at some time received other
hormones. The most commonly prescribed
hormones were oestrogens, usually a short
course after a missed period or to suppress
lactation (270% cases, 22% controls),
and topical corticosteroids (19% cases,
29% controls).
Many women are prescribed medication
which they either never take or take
without understanding its nature. On the
postal questionnaire, women were asked
whether they had ever taken OCs, anti-
hyptertensive drugs, drugs for hormone
deficiency or treatment for acne, or any
other drug for at least 1 month continu-
ously. Only 60/, of both cases and controls
mentioned one or more hormones, i.e.
about one-seventh as many as were identi-
fied from the CxP records. The low level of
reporting by the women themselves con-
trasts with the data on OCs, where there
was reasonable agreement between the
two data sets.
There were no significant differences
between the cases and controls in their
use ofthe other drugs which we specifically
considered phenothiazines, methyldopa
and reserpine. It is, however, interesting
that the GrP records indicated that one-
fifth of each group had been prescribed
phenothiazines, usuallv for relatively
minor psychological problems, often des-
cribed as "depression". Again, the postal
questionnaire data gave a much lower
figure 1% of both cases and controls
mentioned a phenothiazine.
Data were also collected on those
variables which have previously been
shown to be associated with melanoma.
The cases were more likely to describe
themselves as fair-skinned (1200 cases,
900 controls) and to have blonde or red
hair (28% cases, 16% controls). Seventeen
per cent of cases and 210 of controls
gave a history suggestive of chloasma.
When asked about the reaction of their
skin to sun the cases were significantly
more likely to reply that they burned
easily (78% cases, 670o controls, P<
0.05). There were no differences between
cases and controls in the amount of work
or leisure time which they spent out of
doors. However, the cases were slightly
more likely to have spent some of this
time deliberately tanning their legs (7700
cases, 69% controls) and trunk (64% cases,
5300 controls) and were also more likely
to have tanned themselves while on holi-
day abroad (legs-78% cases, 7:3% con-
trols; trunk 7000 cases, 6700 controls),
though these differences were not statis-
tically significant. There was no suggestion
that women with a particular skin colour-
ing were more or less likely to lie in the
sun. The prevalence of sunlamp use was
low, but it was significantly higher in
48ORAL CONTRACEPTIVES AND MIELANOMA
cases than in controls (8% cases, 30o con-
trols, P < 005).
Most women had English parents-
86% ofall parents were English. However,
the cases were more likely to have at
least one Scottish parent. The fathers of
70 cases and 2o% controls (P < 0.05) and
the mothers of 6% cases and 2% controls
(N.S.) were Scottish. When all Celtic
parents were included (Scottish, Welsh
and Irish) the difference between cases
and controls was no longer significant.
The OC use of women was analysed
separately in those with and without
these various risk factors. No consistent
or significant association was found be-
tween OC use and any of the risk factors,
suggesting that confounding did not occur.
Within the various subgroups there was
no significant evidence that OC use either
predisposed to or protected against mela-
noma.
Finally, the data from the Oxford/
Family Planning Association contracep-
tive study showed that there were 12
incident cases of malignant melanoma.
Unexpectedly, the disease was found to be
quite strongly negatively associated with
OC use. Thus the age-standardized inci-
dence rates per 1000 woman-years of
observation were 0 17 in those never
using OCs (8 cases), 0-06 in those using
OCs for up to 4 years (3 cases) and 0-02 in
those using OCs for more than 4 years
(1 case).
DISCUSSION
An important limitation of our case-
control study is that the full range of
information was available only for the
surviving women who responded to our
questionnaire. Fortunately, when the data
on OC use obtained from GP records and
from the postal questionnaire were
checked for each woman, there was reason-
able agreement. It is therefore unlikely
that conflicting findings on OC use would
have emerged had it been possible to
collect information about those who had
died or who were uncooperative by means
of postal questionnaires. Furthermore,
other previously described risk factors for
melanoma such as fair skin (Gellin et al.,
1969; Lee, 1975; Crombie, 1979), blonde
or red hair (Gellin et al., 1969; Nordlund
& Lerner, 1977), and Celtic origin (Lee,
1975; Lane-Brown et al., 1971) were found
to be commoner in the cases than the
controls, suggesting that our data are
likely to be valid.
Since the publication of the paper by
Beral et al. in 1977, Stevens et al. (1980)
have described the results of an analysis
of incidence and mortality rates from
melanoma in a number of different coun-
tries. They found that the recent increases
had occurred equally in both males and
females aged 15-44 years, suggesting that
OC use is of little, if any, significance.
Beral et al. (1977) stressed that statistical
significance was achieved in only one of
their three data sets, though the trends in
all threewereinthe samedirection. No data
wereavailable onpossibleconfoundingvari-
ables which might have played an impor-
tant role in the apparent association.
Any such confounding would be par-
ticularly serious in a sunny climate, and
the UK therefore seemed an appropriate
place to attempt to replicate the Cali-
fornian findings. We did not find any
significant evidence that OCs played a
role in the aetiology of melanoma, though
in the small group ofwomen who had used
OCs for 5 years or more, the questionnaire
data yielded RR of 1P59 (limits 0 83-3.03).
This slightly worrying result is to some
extent offset by the opposite findings in
the Oxford/Family Planning Association
study, but it is clear that more extensive
data about long-term OC use are requred
before firm conclusions can be drawn.
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